Midnight MarketsV1.0
⚠ Not financial adviceNot financial advice. Independent research, not investment recommendations. The author and website make no representation as to accuracy or completeness. Do your own due diligence before acting on anything you read here. Read the full disclaimer →
The Peptide CDMOs — Making the GLP-1 Molecules · The GLP-1 & Bio Supply Chain — Peptides, Bioprocessing & Diagnostics

LONN.SW

Lonza Group
Foreign listing — not directly tradable in a US brokerage. Editorial detail only.

Largest CDMO globally — small molecules, biologics, cell/gene, peptides. Broader exposure than pure-play peptide names.

What they do

Largest CDMO globally — handles small molecules, biologics, cell/gene therapy, and peptides for pharma customers. FY26 sales growth confirmed at 11–12%. Lower-beta diversified way to own the picks-and-shovels theme without single-peptide concentration. Less GLP-1 leverage but more growth durability.